Calidi Biotherapeutics (CLDI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Calidi Biotherapeutics settled a lawsuit with a group of physicians over a stock options dispute by agreeing to issue 200,000 restricted shares and 400,000 warrants to purchase additional shares at $1.32 each, exercisable over five years. The settlement grants the physicians piggy-back rights, allowing them to benefit from any future stock registrations, although Calidi reserves the right to refuse registration if it negatively impacts capital raising efforts. This resolution closes a contentious chapter for the company, potentially clearing the way for smoother financial operations ahead.
For further insights into CLDI stock, check out TipRanks’ Stock Analysis page.